Please login to the form below

Not currently logged in
Email:
Password:

Orchard Therapeutics

This page shows the latest Orchard Therapeutics news and features for those working in and with pharma, biotech and healthcare.

P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

In the last few weeks Sanofi has sold its European generics business to Advent, GlaxoSmithKline divested its rare disease unit to start-up Orchard Therapeutics after buying Novartis out of a

Latest news

  • Sanofi sells European generics to Advent for $2.4bn Sanofi sells European generics to Advent for $2.4bn

    Just this month, for example, GlaxoSmithKline divested its rare disease portfolio to start-up Orchard Therapeutics, after buying Novartis out of a consumer health joint venture in March, and Shire has

  • GSK hands rare disease assets over to Orchard GSK hands rare disease assets over to Orchard

    GSK hands rare disease assets over to Orchard. The UK pharma group will take a 19.9% stake in its ex-rival. ... It has agreed to sign over its entire portfolio of approved and experimental therapies to former rival Orchard Therapeutics.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    Orchard Therapeutics appoints Mark Rothera as CEO. He joins from PTC Therapeutics. ... London, UK-based Orchard Therapeutics has appointed Mark Rothera as its new president and chief executive officer at a time when the group progresses its clinical

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics